

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International patent Classification 4: C07K 13/00, C12N 15/00, C12P 21/02 A61L 27/00, A61K 37/36 // A61K 35/32</p>	A2	<p>(11) International Publication Number: WO 89/09788 (43) International Publication Date: 19 October 1989 (19.10.89)</p>
<p>(21) International Application Number: PCT/US89/01469 (22) International Filing Date: 7 April 1989 (07.04.89) (30) Priority data: 179,406 8 April 1988 (08.04.88) US 232,630 15 August 1988 (15.08.88) US 315,342 23 February 1989 (23.02.89) US</p> <p>(60) Parent Applications or Grants (63) Related by Continuation US 179,406 (CIP) Filed on 8 April 1988 (08.04.88) US 232,630 (CIP) Filed on 15 August 1988 (15.08.88) US 315,342 (CIP) Filed on 23 February 1988 (23.02.88)</p> <p>(71) Applicant (for all designated States except US): CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): OPPERMANN, Hermann [US/US]; 25 Summer Hill Road, Medway, MA 02053 (US). KUBERASAMPATH, Thangavel [IN/US]; 6 Spring Street, Medway, MA 02053 (US). RUEGER, David, C. [US/US];</p>	<p>150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin [TR/US]; 44 Purdue Drive, Milford, MA 01757 (US). (74) Agent: PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US). (81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: BIOSYNTHETIC OSTEOGENIC PROTEINS AND OSTEOGENIC DEVICES CONTAINING THEM</p>		
<p>(57) Abstract</p> <p>Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth and cartilage in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

BIOSYNTHETIC OSTEOGENIC PROTEINS AND
OSTEOGENIC DEVICES CONTAINING THEM

This invention relates to osteogenic devices, to synthetic genes encoding proteins which can induce osteogenesis in mammals and methods for their production using recombinant DNA techniques, to synthetic forms of osteogenic protein, and to bone and cartilage repair procedures using osteogenic device comprising the synthetic proteins.

Mammalian bone tissue is known to contain one or more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the literature as bone-morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

The developmental cascade of bone differentiation consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone differentiation activity of bone matrix can be dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This provides an experimental method for assaying protein extracts for their ability to induce endochondral bone in vivo.

This putative bone inductive protein has been shown to have a molecular mass of less than 50 kilodaltons (kD). Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595).

The potential utility of these proteins has been widely recognized. It is contemplated that the availability of the pure protein would revolutionize orthopedic medicine, certain types of plastic surgery, and various periodontal and craniofacial reconstructive procedures.

The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from

mammalian bone is disclosed by Sampath et al. (Proc. Natl. Acad. Sci. USA (1987) 80). Urist et al. (Proc. Soc. Exp. Biol. Med. (1984) 173:194-199) disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

Urist et al. (Proc. Natl. Acad. Sci. USA (1984) 81:371-375) disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract from bone results in ill-defined and impure preparations.

European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into animals.

International Application No. PCT/087/01537, published January 14, 1988, discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative bone inductive factors produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and apparently expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic proteins, bone induction was not demonstrated. See also Urist et al., EP 0,212,474 entitled Bone Morphogenic Agents.

Wang et al. (Proc. Nat. Acad. Sci. USA (1988) 85: 9484-9488) discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been determined.

Wozney et al. (Science (1988) 242: 1528-1534) discloses the isolation of full-length cDNA's encoding the human equivalents of three

polypeptides originally purified from bovine bone. The authors report that each of the three recombinantly expressed human proteins are independently or in combination capable of inducing cartilage formation. No evidence of bone formation is reported.

It is an object of this invention to provide osteogenic devices comprising matrices containing dispersed osteogenic protein capable of bone induction in allogenic and xenogenic implants. Another object is to provide synthetic osteogenic proteins capable of inducing endochondral bone formation in mammals, including humans. Yet another object is to provide genes encoding non-native osteogenic proteins and methods for their production using recombinant DNA techniques. Another object is to provide novel biosynthetic forms of osteogenic proteins and a structural design for novel, functional osteogenic proteins. Another object is to provide methods for inducing cartilage formation.

These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

Summary of the Invention

This invention involves osteogenic devices which, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation and bone marrow differentiation. Suitably modified as disclosed herein, the devices also may be used to induce cartilage formation. The devices comprise a carrier material, referred to herein as a matrix, having the characteristics disclosed below, containing dispersed osteogenic protein in the form of a biosynthetic construct.

Key to these developments was the successful preparation of substantially pure osteogenic protein by purification from bone, the elucidation of amino acid sequence and structure data of the native osteogenic protein, and insights involving study of the DNA and amino acid sequences of the natural source product. A protocol was developed which results in retrieval of active, substantially pure osteogenic protein from mammalian bone. Investigation of the properties and structure of the native form osteogenic protein then permitted the inventors to develop a rational design for non-native forms, i.e., forms never before known in nature, capable of inducing bone formation. As far as applicants are aware, the constructs disclosed herein constitute the first instance of the design of a functional, active protein without preexisting knowledge of the active region of a native form nucleotide or amino acid sequence.

A series of consensus DNA sequences were designed with the goal of producing an active osteogenic protein. The sequences were based on partial amino acid sequence data obtained from the naturally sourced product and on observed homologies with unrelated genes reported in the literature, or the sequences they encode, having a presumed or demonstrated developmental function. Several of the biosynthetic consensus sequences have been expressed as fusion proteins in procaryotes, purified, cleaved, refolded, combined with a matrix, implanted in an established animal model, and shown to have endochondral bone-inducing activity. The currently preferred active proteins comprise sequences designated COP5, COP7, COP16, and OP1. The amino acid sequences of these proteins are set forth below.

```

1      10      20      30      40
COP5  LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPFPLAD
      50      60      70
      HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
      80      90      100
      ISMLYLDENEKVVVLKNYQEMVVEGCGCR

1      10      20      30      40
COP7  LYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
      50      60      70
      HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
      80      90      100
      ISMLYLDENEKVVVLKNYQEMVVEGCGCR

-10
      PKHHSQRARKKNKN
1      10      20      30      40
COP16 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGECPFPLAD
      50      60      70
      HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
      80      90      100
      ISMLYLDENEKVVVLKNYQEMVVEGCGCR

```

- 8 -

```

                                -5
                                HQRQA
                                40
OPl      1          10          20          30
          CKKHELYVSFR-DLQWQDWIIAPEGYAAYYCEGECAPFLNS
                                50          60          70
          YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
          80          90          100
          ISVLYFDDSSNVILKKYRNMVVRACGCH

```

In these sequences and all other amino acid sequences disclosed herein, the dashes (-) are used as fillers only to line up comparable sequences in related proteins, and have no other function. Thus, amino acids 45-50 of COP7, for example, are NHAHV. Also, the numbering of amino acids is selected solely for purposes of facilitating comparisons between sequences. Thus, for example, the DF residues numbered at 9 and 10 of COP5 and COP7 may comprise residues, e.g., 35 and 36, of an osteogenic protein embodying the invention. Various leader or trailer sequences may be attached to the operative active region provided the osteogenic or chondrogenic activity of the protein is not destroyed.

Thus, in one aspect, the invention comprises a protein comprising an amino acid sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OPl such that it is capable of inducing endochondral bone formation when properly folded and implanted in a mammal in association with a matrix. Some of these sequences induce cartilage,

but not bone. Also, the bone forming materials may be used to produce cartilage if implanted in an avascular locus, or if an inhibitor to full bone development is implanted together with the active protein. Thus, in another aspect, the invention comprises a protein less than about 200 amino acids long (for each chain) including a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OPl such that it is capable at least of cartilage formation when properly folded and implanted in a mammal in association with a matrix. The phrase "sufficiently duplicative", as used herein, is used to describe proteins having a degree of homology with the specific sequences disclosed herein and other, different amino acids but which nevertheless exhibit osteogenic or chondrogenic activity.

In one preferred aspect, these proteins comprise species of the generic amino acid sequences:

```

1      10      20      30      40      50
  LXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90      100
QXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

or

```

1      10      20      30      40      50
CXXXLXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90      100
QXXVXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

where the letters indicate the amino acid residues of standard single letter code, and the Xs each represent any one of the 22 naturally occurring amino acid residues. Preferred amino acid sequences within the foregoing generic sequences are:

```

1      10      20      30      40      50
  LYVDFRDVGWNDWIVAPPGYHAFYCHGECFPFLADHLNSTNHAIV
    K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
    F E K I  DN   L   N S  Q  ITK F P   TL
      A   S   K
      60      70      80      90      100
QTLVNSVNP GKIPKACCVPT ELSAISMLYLDENENVV LKNYQDMVVEGCGCR
SI HAI SEQV EP  A  EQMNSLAI FFNDQDK I RK EE T DA H H
  RF  T  S      K DPV V  Y N S      H RN  RS
  N   S                K          P   E

```

and

```

1      10      20      30      40      50
CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECFPFLADHLNSTNHAIV
RRRS K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
  KE F E K I  DN   L   N S  Q  ITK F P   TL
    Q   A   S   K
      60      70      80      90      100
QTLVNSVNP GKIPKACCVPT ELSAISMLYLDENENVV LKNYQDMVVEGCGCR
SI HAI SEQV EP  A  EQMNSLAI FFNDQDK I RK EE T DA H H
  RF  T  S      K DPV V  Y N S      H RN  RS
  N   S                K          P   E

```

wherein each of the amino acids arranged vertically at each position in the sequence may be used alternatively in various combinations. Note that these generic sequences have 6 and preferably 7 cysteine residues where inter- or intramolecular disulfide bonds can form, and contain other critical amino acids which influence the tertiary structure of the proteins. These generic structural features are found in previously published sequences, none of which have been described as capable of osteogenic activity, and most of which never have been linked with such activity.

Particular useful sequences include:

Vg1	1	10	20	30	40
	CKKRHLYVEFK-DVGWQNWVIAPOGYMANCYGECPYPLTE				
		50	60	70	
	ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP				
	80	90	100		
	ISMLFYDNNNDNVVLRHYENMAVDECGCR				
DPP	1	10	20	30	40
	CRRHSLYVDFS-DVGWDDWIVAPLGYDAYYCHGKCPFPLAD				
		50	60	70	
	HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS				
	80	90	100		
	VAMLYLNDQSTVVLKQEMTVVVGCGCR				
CBMP-2a	1	10	20	30	40
	CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD				
		50	60	70	
	HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA				
	80	90	100		
	ISMLYLDENEKVVLKQDMVVEGCGCR				

CBMP-2b 1 10 20 30 40
 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
 80 90 100
 ISMLYLDEYDKVVLKKNYQEMVVEGCGCR

CBMP-3 1 10 20 30 40
 CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMPK
 50 60 70
 SLKPSN--H-ATIQSIVRAVGVVPGIPEPCCVPEKMSS
 80 90 100
 LSILFFDENKNVVLKVYPNMTVESACR

COP1 1 10 20 30 40
 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
 80 90 100
 ISMLYLDENSTVVLKKNYQEMTVVGGCGR

COP3 1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

COP4 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTELSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

- 14 -

derived. In view of this disclosure, skilled genetic engineers can design and synthesize genes which encode appropriate amino acid sequences, and then can express them in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active synthetic proteins comprising truncated analogs, muteins, fusion proteins, and other constructs mimicking the biological activity of the native forms and capable of inducing bone formation in mammals including humans.

The synthetic proteins are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles or porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The particle size should be within the range of 70 - 850 μm , preferably 70 - 420 μm . It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-inflammatory) and, biodegradable in vivo to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and particulate, deglycosylated (or HF treated), protein extracted, demineralized, xenogenic bone.

Optionally, such xenogenic bone powder matrices also may be treated with proteases such as trypsin. Other useful matrix materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

The osteogenic proteins and implantable osteogenic devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1:959-963). The devices may be used to induce local endochondral bone formation in non-union fractures, and in other clinical applications including periodontal applications where bone formation is required. Another potential clinical application is in cartilage repair, for example, in the treatment of osteoarthritis.

- 16 -

Brief Description of the Drawing

The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1 is a comparison of the amino acid sequence of various osteogenic proteins to those of the TGF-beta family. COP1, COP3, COP4, COP5, and COP7 are a family of analogs of synthetic osteogenic proteins developed from the consensus gene that was joined to a leader protein via a hinge region having the sequence D-P-N-G that permitted chemical cleavage at the D-P site (by acid) or N-G (by hydroxylamine) resulting in the release of the analog protein; VGI is a Xenopus protein, DPP is a Drosophila protein; OP1 is a native osteogenic protein; CBMP2a and 2b, and CBMP3 are subparts of proteins disclosed in PCT application 087/01537; MIS is Mullerian inhibitory substance; and "consensus choices" represent various substitutions of amino acids that may be made at various positions in osteogenic proteins;

FIGURE 2A is an E. coli expression vector containing a gene of an osteogenic protein fused to a leader protein;

FIGURE 2B is the DNA sequence comprising a modified trp-LE leader, two Fb domains of protein A, an ASP-PRO cleavage site, and the COP5 sequence;

FIGURES 3A and 3B are photomicrographs of implants showing the histology (day 12) of COP5 active recombinant protein. A is a control (rat matrix alone, 25 mg). B is rat matrix plus COP5, showing +++ cartilage formation and ++ bone formation (see key infra). Similar results are achieved with COP7; and

FIGURE 4 is a schematic representation of the DNA sequence and corresponding amino acid sequence of a consensus gene for osteogenic protein (COPO).

Description

Purification protocols have been developed which enable isolation of the osteogenic protein present in crude protein extracts from mammalian bone. The isolation procedure enables the production of significant quantities of substantially pure osteogenic protein from any mammalian species, provided sufficient amounts of fresh bone from the species is available. The empirical development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP has been characterized significantly; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat have been studied; it has been shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts; and it may be used to induce formation of endochondral bone in orthopedic defects including non-union fractures. In its native form it is a glycosylated, dimeric protein. However, it is active in deglycosylated form. It has been partially sequenced.

Elucidation of the amino acid sequence of BOP enabled the construction of a consensus nucleic acid sequence designed as disclosed herein based on the sequence data, inferred codons for the sequences, and observation of partial homology with known genes.

These consensus sequences have been refined by comparison with the sequences present in certain regulatory genes from drosophila, xenopus, and human followed by point mutation, expression, and assay for activity. This approach has been successful in producing several active ~~totally synthetic constructs~~ not found in nature (as far as applicants are aware) which have true osteogenic activity.

These discoveries enable the construction of DNAs encoding totally novel, non-native protein constructs which individually and combined are capable of producing true endochondral bone. The DNAs may be expressed using well established recombinant DNA technologies in procaryotic or eucaryotic host cells, and the expressed proteins may be oxidized and refolded in vitro if necessary for biological activity.

The design and production of such biosynthetic proteins, the nature of the matrix, and other material aspects concerning the nature, utility, how to make, and how to use the subject matter claimed herein will be further understood from the following, which constitutes the best method currently known for practicing the various aspects of the invention.

CONSENSUS SEQUENCE DESIGN

A synthetic consensus gene shown in FIGURE 4 was designed to encode a consensus protein based on amino acid predictions from homology with the

TGF-beta gene family. The designed consensus sequence was then constructed using known techniques involving assembly of oligonucleotides manufactured in a DNA synthesizer.

~~Tryptic peptides derived from Bovine~~
Osteogenic Protein isolated by applicants and sequenced by Edman degradation provided amino acid sequences that showed strong homology with the Drosophila DPP protein sequence (as inferred from the gene), the Xenopus VGl protein, and somewhat less homology to inhibin and TGF-beta, as demonstrated below in TABLE 1.

TABLE 1

<u>protein</u>	<u>amino acid sequence</u>	<u>homology</u>
(<u>BOP</u>)	SFDAYYCSGACQFPS ***** * * * *	(9/15 matches)
(<u>DPP</u>)	GYDAYYCHGKCPFFL	
(<u>BOP</u>)	SFDAYYCSGACQFPS * * * * *	(6/15 matches)
(<u>Vgl</u>)	GYMANYCYGECPYPL	
(<u>BOP</u>)	SFDAYYCSGACQFPS * * * * *	(5/15 matches)
(<u>inhibin</u>)	GYHANYCEGECPSHI	
(<u>BOP</u>)	SFDAYYCSGACQFPS * * * * *	(4/15 matches)
(<u>TGF-beta</u>)	GYHANFCLGPCPYIW	
(<u>BOP</u>)	K/RACCVPTELSAISMLYLDEN ***** * * * * * *	(12/20 matches)
(<u>Vgl</u>)	LPCCVPTKMSPI SMLFYDNN	
(<u>BOP</u>)	K/RACCVPTELSAISMLYLDEN * * * * * * * * * *	(12/20 matches)
(<u>inhibin</u>)	KSCCVPTKLRPMSMLYDDG	
(<u>BOP</u>)	K/RACCVPTELSAISMLYLDE **** * *	(6/19 matches)
(<u>TGF-beta</u>)	APCCVPQALEPLPIVYYVG	
(<u>BOP</u>)	K/RACCVPTELSAISMLYLDEN ***** * * * *	(12/20 matches)
(<u>DPP</u>)	KACCVPTQLDSVAMLYLNDQ	

- 22 -

(<u>BOP</u>)	LYVDF	
	*****	(5/5 matches)
(<u>DPP</u>)	LYVDF	

(<u>BOP</u>)	LYVDF	
	*** *	(4/5 matches)
(<u>Vgl</u>)	LYVEF	

(<u>BOP</u>)	LYVDF	
	** **	(4/5 matches)
(<u>TGF-beta</u>)	LYIDF	

(<u>BOP</u>)	LYVDF	
	* *	(2/5 matches)
(<u>inhibin</u>)	FFVSF	

*-match

In determining an appropriate amino acid sequence of an osteogenic protein (from which the nucleic acid sequence can be determined), the following points were considered: (1) the amino acid sequence determined by Edman degradation of natural source osteogenic protein tryptic fragments is ranked highest as long as it has a strong signal and shows homology or conservative changes when aligned with the other members of the gene family; (2) where the sequence matches for all four proteins, it is used in the synthetic gene sequence; (3) matching amino acids in DPP and Vgl are used; (4) If Vgl or DPP diverged but either one were matched by inhibin or by TGF-beta, this matched amino acid is chosen; (5) where all sequences diverged, the DPP sequence is initially chosen, with a later plan of creating the

Vgl sequence by mutagenesis kept as a possibility. In addition, the consensus sequence is designed to preserve the disulfide crosslinking and the apparent structural homology among the related proteins.

RECOMBINANT OSTEOGENIC PROTEIN CONSTRUCTS

This approach resulted in the production of novel recombinant proteins capable of inducing formation of cartilage and endochondral bone comprising a protein structure analogous to or duplicative of the functional domain of the naturally sourced material. The amino acid sequences encoded by the consensus DNA sequences were derived from a family of natural proteins implicated in tissue development. These gene products/proteins are known to exist in active form as dimers and are, in general, processed from a precursor protein to produce an active C-terminal domain of the precursor.

The recombinant osteogenic/chondrogenic proteins are "novel" in the sense that, as far as applicants are aware, they do not exist in nature or, if they do exist, have never before been associated with bone or cartilage formation. The approach to design of these proteins is to employ amino acid sequences, found in the native OP isolates, in polypeptide structures are patterned after certain proteins reported in the literature, or the amino acid sequences inferred from DNAs reported in the literature. Thus, using the design criteria set

forth above, and refining the amino acid sequence as more protein sequence information was learned, a series of synthetic proteins were designed with the hope and intent that they might have osteogenic or chondrogenic activity when tested in the bioassay system disclosed below.

It was noted, for example, that DPP from *Drosophila*, VGI from *Xenopus*, the TGF beta family of proteins, and to a lesser extent, alpha and beta inhibins, had significant homologies with certain of the sequences derived from the naturally sourced OP product. (FIGURE 1.) Study of these proteins led to the realization that a portion of the sequence of each had a structural similarity observable by analysis of the positional relationship of cysteines and other amino acids which have an important influence on three dimensional protein conformation. It was noted that a region of these sequences had a series of seven cysteines, placed very nearly in the same relative positions, and certain other amino acids in sequence as set forth below:

```

          10          20          30          40          50
CXXXXLXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXX
          60          70          80          90         100
QXXVXXXNXXXXPXXCCPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX

```

wherein each X independently represents an amino acid. Expression experiments of two of these constructs demonstrate activity. Expression experiments with constructs patterned after this template amino acid sequence with a shorter sequence having only six cysteines also show activity:

- 25 -

```

      10      20      30      40      50
LXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCX

```

wherein each X independently represents an amino acid. Within these generic structures are a multiplicity of specific sequences which have osteogenic or chondrogenic activity. Preferred structures are those having the amino acid sequence:

```

      10      20      30      40      50
CKRHPLYVDFRDVGNWVIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
RKRS K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
KE F E K I  DN   L   N S   Q  ITK F P   TL
Q      A      S      K
      60      70      80      90     100
QTLVNSVNPVKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
SI HAI SEQV EP  A EQMNSLAI FFNDQDK I RK EE T DA H H
RF      T      S      K DPV V  Y N S      H RN  RS
N      S                                  K      P      E

```

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be used. Novel active proteins also are defined by amino acid sequences comprising an active domain beginning at residue number 6 of this sequence, i.e., omitting the N terminal CXXXX, or omitting any of the preferred specific combinations such as CKRHP, CRRKQ, CKRHE, etc, resulting in a construct having only six cysteine residues. After this work, PCT 87/01537 was published, and it was observed that the proteins there identified as BMPII a and b and BMPIII each included a region embodying this generic structure. These proteins were not demonstrated to be osteogenic in the published application. However, applicants

discovered that a subpart of the amino acid sequence of these proteins, properly folded, and implanted as set forth herein, is active. These are disclosed herein as CBMPIIa, CBMPIIb, and CBMPIII. Also, applicants retrieved a previously unreported gene by probing a human genomic DNA library with COPO. This protein was designated OPl. It comprises a region exhibiting the same generic structure.

Thus, the preferred osteogenic proteins are expressed from recombinant DNA and comprise amino acid sequences including any of the following sequences:

```

Vg1      1      10      20      30      40
         CKKRHLYVEFK-DVGWQNWVIAPOGYMANYCYGECPYPLTE
                   50      60      70
         ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
                   80      90     100
         ISMLFYDNNNDNVVLRHYENMAVDECGCR

DPP      1      10      20      30      40
         CRRHSLYVDFS-DVGWDDWIVAPLGDAYYCHGKCPFPLAD
                   50      60      70
         HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
                   80      90     100
         VAMLYLNDQSTVVLKKNYQEMTVVGCGR

OPl      1      10      20      30      40
         LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFFLNS
                   50      60      70
         YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
                   80      90     100
         ISVLYFDDSSNVILKKYRNMVVRACGCH

```

-5
HQRQA

OPI 1 10 20 30 40
 CKKHELYVSFR-DLWQDWIIAPEGYAAAYCEGECAPPLNS
 50 60 70
 YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
 80 90 100
 ISVLYFDDSSNVILKKYRNMVVRACGCH

CBMP-2a 1 10 20 30 40
 CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQDMVVEGCGCR

CBMP-2b 1 10 20 30 40
 CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
 50 60 70
 HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA
 80 90 100
 ISMLYLDEYDKVVLKNYQEMVVEGCGCR

CBMP-3 1 10 20 30 40
 CARRYLKVDFA-DIGWSEWII SPKSFDAYYCSGACQFPMPK
 50 60 70
 SLKPSN--H-ATIQSIVRAVGVPPIPEPCCVPEKMSS
 80 90 100
 LSILFFDENKNVVLKVYPNMTVESACR

COP1 1 10 20 30 40
 LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENSTVVLKNYQEMTVVGGCGCR

COP3 1 10 20 30 40
 LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPBK-VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVLKNYQEMVVEGCGCR

COP4 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
 50 60 70
 HFNSTN--H-AVVQTLVNNMNPVK--VPKPCCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

COP5 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

COP7 1 10 20 30 40
 LYVDFS-DVGWDDWIVAPPGYHAFYCHGECPPFLAD
 50 60 70
 HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

 10
 PKHHSQRARKKNKN

COP16 1 10 20 30 40
 CRRHSLYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
 50 60 70
 HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
 80 90 100
 ISMLYLDENEKVVVLKKNYQEMVVEGCGCR

As shown in FIGURE 1, these sequences have considerable homology with the alpha and beta inhibins, three forms of TGF beta, and MIS.

Gene Preparation

The synthetic genes designed to express the proteins as described above preferably are produced by assembly of chemically synthesized oligonucleotides. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer (TBE). The DNA is then electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE. Natural gene sequences and cDNAs also may be used for expression.

Expression

The genes can be expressed in appropriate prokaryotic hosts such as various strains of E. coli and also in bacillus, yeasts, and various animal cells such as CHO, myeloma, etc. Generally, expression may be achieved using many cell types and expression systems well known to those skilled in the art. If the gene is to be expressed in E. coli, it must first be cloned into an expression vector. An expression vector (FIGURE 2A) based on pBR322 and containing a synthetic trp promoter operator and the modified trp LE leader can be opened at the EcoRI and PSTI restriction sites, and a FB-FB COP1, COP3, COP5, and COP7 gene fragments (FIGURE 2B) can be inserted between these sites, where FB is fragment B of Staphylococcal Protein A. The expressed fusion

protein results from attachment of the COP gene to a fragment encoding FB. The COP protein is joined to the leader protein via a hinge region having the sequence Asp-Pro-Asn-Gly. This hinge permits chemical cleavage of the fusion protein with dilute acid at the asp-pro site or cleavage at Asn-Gly with hydroxylamine, resulting in release of the COP protein. For COP16 and OP1, the proteins are expressed as fusion products, using the modified trp-LE as a leader.

Production of Active Proteins

The following procedure was followed for production of active recombinant proteins. E. coli cells containing the fusion proteins were lysed. The fusion proteins were purified by differential solubilization. In the case of the COP1, 3, 4, 5, and 7 fusion proteins, cleavage was with dilute acid, and the resulting cleavage products were passed through a Sephacryl-200HR column. The Sephacryl column separated most of the uncleaved fusion products from the COP1, 3, 4, 5, and 7 analogs. In the case of the COP16 or OP1 fusion protein, cleavage was with a more concentrated acid, and an SP-Trisacryl column was used as an additional purification step. The COP or OP fractions were then subjected to HPLC on a semi-prep C-18 column.

Initial conditions for refolding of COP analogs or OP1 were at pH 8.0 using Tris, Gu-HCl, dithiothreitol. Final conditions for refolding of

COP analogs were at pH 8.0 using Tris, oxidized glutathione, and lower amounts of Gu-HCl and dithiothreitol. Alternatively, the COP or OP1 proteins are suspended in 50 mM HCl, 6 M guanidine-HCl, pH 8.0, for 18 hours at 4°C. Refolding may not be required if the proteins are expressed in animal cells.

Production of Antisera

Antisera to COP7 and COP5 were produced in New Zealand white rabbits. Western blots demonstrate that the antisera react with COP7 and COP5 preparations. Antisera to COP7 has been tested for reactivity to naturally sourced bovine osteogenic protein samples. Western blots show a clear reaction with the 30 kD protein and, when reduced, with the 16 kD subunit. The immunoreactive species appears as a ~~closely-spaced doublet in the 16 kD subunit region,~~ similar to the 16 kD doublet seen in Con A blots.

MATRIX PREPARATION

General Consideration of Matrix Properties

The carrier described in the bioassay section, *infra*, may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., HAP, collagen, tricalcium phosphate, or polylactic acid, polyglycolic acid and various copolymers thereof). Also xenogeneic bone may be used if pretreated as described below.

Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 and 420 μm elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate osteogenic protein onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

The sequential cellular reactions at the interface of the bone matrix/OP implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be

biocompatible in vivo and biodegradable; the carrier must act as a temporary scaffold until replaced completely by new bone. Biocompatibility requires that the matrix not induce significant inflammation when implanted and not be rejected by the host animal. Biodegradability requires that the matrix be slowly absorbed by the body of the host during development of new bone or cartilage. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates in vivo. In bones, the dissolution rates can vary according to whether the implant is placed in cortical or trabecular bone.

Matrix geometry, particle size, the presence of surface charge, and porosity or the presence of interstices among the particles of a size sufficient to permit cell infiltration, are all important to successful matrix performance. It is preferred to shape the matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

The matrix may comprise a shape-retaining solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue. Masticated muscle or other tissue may also be used. Large allogeneic bone implants can act as a

carrier for the matrix if their marrow cavities are cleaned and packed with particles and the dispersed osteogenic protein.

Preparation of Biologically Active Allogenic Matrix

Demineralized bone matrix is prepared from the dehydrated diaphyseal shafts of rat femur and tibia as described herein to produce a bone particle size which pass through a 420 μm sieve. The bone particles are subjected to dissociative extraction with 4 M guanidine-HCl. Such treatment results in a complete loss of the inherent ability of the bone matrix to induce endochondral bone differentiation. The remaining insoluble material is used to fabricate the matrix. The material is mostly collagenous in nature, and upon implantation, does not induce cartilage and bone. All new preparations are tested for mineral content and false positives before use. The total loss of biological activity of bone matrix is restored when an active osteoinductive protein fraction or a pure protein is reconstituted with the biologically inactive insoluble collagenous matrix. The osteoinductive protein can be obtained from any vertebrate, e.g., bovine, porcine, monkey, or human, or produced using recombinant DNA techniques.

Preparation of Deglycosylated Bone Matrix for Use in Xenogenic Implant

When osteogenic protein is reconstituted with collagenous bone matrix from other species and implanted in rat, no bone is formed. This suggests that while the osteogenic protein is xenogenic (not species specific), while the matrix is species specific and cannot be implanted cross species perhaps due to intrinsic immunogenic or inhibitory components. Thus, heretofore, for bone-based matrices, in order for the osteogenic protein to exhibit its full bone inducing activity, a species specific collagenous bone matrix was required.

The major component of all bone matrices is Type I collagen. In addition to collagen, extracted bone includes non-collagenous proteins which may account for 5% of its mass. Many non-collagenous components of bone matrix are glycoproteins. Although the biological significance of the glycoproteins in bone formation is not known, they may present themselves as potent antigens by virtue of their carbohydrate content and may constitute immunogenic and/or inhibitory components that are present in xenogenic matrix.

It has now been discovered that a collagenous bone matrix may be used as a carrier to effect bone inducing activity in xenogenic implants, if one first removes the immunogenic and inhibitory

components from the matrix. The matrix is deglycosylated chemically using, for example, hydrogen fluoride to achieve this purpose.

Bovine bone residue prepared as described above is sieved, and particles of the 74-420 μM are collected. The sample is dried in vacuo over P_2O_5 , transferred to the reaction vessel and anhydrous hydrogen fluoride (HF) (10-20 ml/g of matrix) is then distilled onto the sample at -70°C . The vessel is allowed to warm to 0°C . and the reaction mixture is stirred at this temperature for 120 min. After evaporation of the HF in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid.

Extent of deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with HF, after washing the samples appropriately to remove non-covalently bound carbohydrates.

The deglycosylated bone matrix is next treated as set forth below:

- 1) suspend in TBS (Tris-buffered Saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) and stir at RT for 30 min;

- 2) centrifuge and wash with TBS or UTBS as in step 1; and
- 3) centrifuge; discard supernatant; water wash residue; and then lyophilize.

FABRICATION OF DEVICE

Fabrication of osteogenic devices using any of the matrices set forth above with any of the osteogenic proteins described above may be performed as follows.

A. Ethanol precipitation

In this procedure, matrix is added to osteogenic protein in guanidine-HCl. Samples are vortexed and incubated at a low temperature. Samples are then further vortexed. Cold absolute ethanol is added to the mixture which is then stirred and incubated. After centrifugation (microfuge high speed) the supernatant is discarded. The reconstituted matrix is washed with cold concentrated ethanol in water and then lyophilized.

B. Acetonitrile Trifluoroacetic Acid Lyophilization

In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution is added to the carrier. Samples are vigorously vortexed many times and then lyophilized.

C. Urea Lyophilization

For those proteins that are prepared in urea buffer, the protein is mixed with the matrix, vortexed many times, and then lyophilized. The lyophilized material may be used "as is" for implants.

IN VIVO RAT BIOASSAY

Several of the synthetic proteins have been incorporated in matrices to produce osteogenic devices, and assayed in rat for endochondral bone. Studies in rats show the osteogenic effect to be dependent on the dose of osteogenic protein dispersed in the osteogenic device. No activity is observed if the matrix is implanted alone. The following sets forth guidelines for how the osteogenic devices disclosed herein can be assayed for evaluating protein constructs and matrices for biological activity.

A. Subcutaneous Implantation

The bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80: 6591-6595), herein incorporated by reference, is used to assess endochondral bone differentiation activity. This assay consists of implanting the test samples in subcutaneous sites in

allogenic recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is designated as day one of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

B. Cellular Events

The implant model in rats exhibits a controlled progression through the stages of matrix induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

C. Histological Evaluation

Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Implants are fixed in Bouins Solution, embedded in parafilm, cut into 6-8 mm sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of endochondrial bone. Twelve day implants are usually sufficient to determine whether the implants show bone inducing activity.

D. Biological Markers

Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be determined spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology should have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the implants are removed from the rat. Alternatively the amount of bone formation can be determined by measuring the calcium content of the implant.

The osteogenic activity due to osteogenic protein is represented by "bone forming units". One bone forming unit represents the amount of protein that is needed for half maximal bone forming activity as compared to rat demineralized bone matrix as control and determined by calcium content of the implant on day 12.

Devices that contained only rat carrier show complete absence of new bone formation. The implant consists of carrier rat matrix and surrounding mesenchymal cells. Again, the devices that contained rat carrier and not correctly folded (or biologically inactive) recombinant protein also showed complete absence of bone formation. These implants are scored as cartilage formation (-) and bone formation (-). The endochondral bone formation activity is scored as zero percent (0%) (FIGURE 3A).

Implants included biologically active recombinant protein, however, showed evidence of endochondral bone formation. Histologically they showed new cartilage and bone formation.

The cartilage formation is scored as (+) by the presence of metachromatically stained chondrocytes in the center of the implant, as (++) by the presence of numerous chondrocytes in many areas of the implant and as (+++) by the presence of abundant chondrocytes forming cartilage matrix and the appearance of hypertrophied chondrocytes accompanying cartilage calcification (FIGURE 3B).

The bone formation is scored as (+) by the presence of osteoblast surrounding vascular endothelium forming new matrix, as (++) by the formation of bone due to osteoblasts (as indicated by arrows) and further bone remodeling by the appearance of osteoclasts in opposition to the newly formed bone matrix. Vascular invasion is evident in these implants (FIGURE 3B). Formation is scored as (+++) by the presence of extensive remodeled bone which results in the formation of ossicles.

The overall bone inducing activity due to recombinant protein is represented as percent response of endochondral bone formation (see TABLE 2 below).

TABLE 2

HISTOLOGICAL EVALUATION OF RECOMBINANT BONE INDUCTIVE
PROTEINS

<u>Sample No.</u>	<u>Implanted Protein</u>	<u>Cartilage Formation</u>	<u>Bone Formation</u>
260-54	COP-5	+++	++
279-5	COP-5	++	+
285-13	COP-5	+++	++
277-7	COP-7	+++	++
277-8	COP-7	+++	++
277-9	COP-7	++	+
285-14	COP-7	+++	++
285-24	COP-7	++	+
285-25	COP-7	++	++
314-6	COP-16	+++	+++
314-15	COP-16	++	+
314-16	COP-16	++	+
314-12	OP-1	++	+

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all

changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims

1. An osteogenic device for implantation in a mammal, said device comprising:

a biocompatible, in vivo biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and

a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains, each of which comprises an amino acid sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing endochondral bone formation in association with said matrix when implanted in a mammal.

2. A device for implantation in a mammal, said device comprising:

a biocompatible, in vivo biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and

a protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains, each of which has less than about 200 amino acids, and each of which comprises a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing cartilage formation in association with said matrix when implanted in a mammal.

3. The device of claim 1 or 2 wherein the sequence comprises:

```

      10      20      30      40      50
CXXXLXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXNXXXXPXXCCPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
    
```

wherein each X independently represents an amino acid.

4. The device of claim 1 or 2 wherein the sequence comprises:

```

      10      20      30      40      50
LXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXNXXXXPXXCCPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
    
```

wherein each X independently represents an amino acid.

5. The device of claim 1 or 2 wherein the sequence comprises:

```

      10      20      30      40      50
CKRHPLYVDFRDVGVNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
  RKRS K S S L QE VIS E FD Y E A AY MPESMKAS VI
    KE F E K I DN L N S Q ITK F P TL
      Q A S K
      60      70      80      90      100
QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
  SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
    RF T S K DPV V Y N S H RN RS
      N S K P E
    
```

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

6. The device of claim 1 or 2 wherein the sequence comprises:

```

      10      20      30      40      50
LYVDFRDVGVNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
  K S S L QE VIS E FD Y E A AY MPESMKAS VI
    F E K I DN L N S Q ITK F P TL
      A S K
      60      70      80      90      100
QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
  SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
    RF T S K DPV V Y N S H RN RS
      N S K P E
    
```

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

7. The device of claim 1 or 2 wherein the sequence comprises:

```

Vg1      1      10      20      30      40
         CKKRHLYVEFK-DVGWQNWVIAPOGYMANYCYGECPYPLTE
           50      60      70
         ILNGSN--H-AILQTLVHSIEPED-IPLPCCVPTKMSP
           80      90     100
         ISMLFYDNNNDNVVLRHYENMAVDECGCR
    
```

8. The device of claim 1 or 2 wherein the sequence comprises:

```

DPP      1      10      20      30      40
         CRRHSLYVDFS-DVGWDDWIVAPLGYDAYYCHGKCPFPLAD
           50      60      70
         HFNSTN--H-AVVQTLVNNNNPGK-VPKACCVPTQLDS
           80      90     100
         VAMLYLNDQSTVVLKQNYQEMTVVGCGR
    
```

9. The device of claim 1 or 2 wherein the sequence comprises:

```

OPI      1      10      20      30      40
         LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPPLNS
           50      60      70
         YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
           80      90     100
         ISVLYFDDSSNVILKKYRNMVVRACGCH
    
```

10. The device of claim 1 or 2 wherein the sequence comprises:

				-5	
				HQRQA	
OPI	1	10	20	30	40
	CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFPPLNS				
		50	60	70	
	YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA				
	80	90	100		
	ISVLYFDDSSNVILKKYRNMVVRACGCH				

11. The device of claim 1 or 2 wherein the sequence comprises:

CBMP-2a	1	10	20	30	40
	CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPPLAD				
		50	60	70	
	HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA				
	80	90	100		
	ISMLYLDENEKVVLKKNYQDMVVEGCGCR				

12. The device of claim 1 or 2 wherein the sequence comprises:

CBMP-2b	1	10	20	30	40
	CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPPPLAD				
		50	60	70	
	HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA				
	80	90	100		
	ISMLYLDEYDKVVLKKNYQEMVVEGCGCR				

13. The device of claim 1 or 2 wherein the sequence comprises:

```

1           10           20           30           40
CBMP-3     CARRYLKVDFA-DIGWSEWIIISPKSFDAYYC SGACQFPMPK
           50           60           70
           SLKPSN--H-ATIQSIVRAVG VVPGIPEPCCVPEKMSS
           80           90           100
           LSILFFDENKNVVLKVYPNMTVESCACR

```

14. The device of claim 1 or 2 wherein the sequence comprises:

```

1           10           20           30           40
COP1       LYVDFQRDVGWDDWIIAPVDFDAYYC SGACQFP SAD
           50           60           70
           HFNSTN--H-AVVQTLVNNMNP GK-VPKCCVPT ELSA
           80           90           100
           ISMLYLDENSTVVLK NYQEMTVVGC GCR

```

15. The device of claim 1 or 2 wherein the sequence comprises:

```

1           10           20           30           40
COP3       LYVDFQRDVGWDDWIVAPPGYQAFYC SGACQFP SAD
           50           60           70
           HFNSTN--H-AVVQTLVNNMNP GK-VPKCCVPT ELSA
           80           90           100
           ISMLYLDENEKVVLK NYQEMVVEGC GCR

```

16. The device of claim 1 or 2 wherein the sequence comprises:

```

1           10           20           30           40
COP4       LYVDFS-DVGWDDWIVAPPGYQAFYC SGACQFP SAD
           50           60           70
           HFNSTN--H-AVVQTLVNNMNP GK-VPKCCVPT ELSA
           80           90           100
           ISMLYLDENEKVVLK NYQEMVVEGC GCR

```

17. The device of claim 1 or 2 wherein the sequence comprises:

```

1           10           20           30           40
COP5      LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
           50           60           70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
           80           90           100
ISMLYLDENEKVVLKKNYQEMVVEGCGCR
    
```

18. The device of claim 1 or 2 wherein the sequence comprises:

```

1           10           20           30           40
COP7      LYVDFS-DVGWNDWIVAPPGYHAFYCHGECPPFLAD
           50           60           70
HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
           80           90           100
ISMLYLDENEKVVLKKNYQEMVVEGCGCR
    
```

19. The device of claim 1 or 2 wherein the sequence comprises:

```

                                           10
                                           PKHHSQRARKKNKN
1           10           20           30           40
COP16     CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGECPPFLAD
           50           60           70
HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
           80           90           100
ISMLYLDENEKVVLKKNYQEMVVEGCGCR
    
```

20. The device of claim 1 or 2 wherein the osteogenics protein comprises a pair of separate polypeptide chains.

21. Osteogenic protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains each of which comprises a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing endochondral bone formation in association with a matrix when implanted in a mammal.

22. A protein, produced by expression of recombinant DNA in a host cell, comprising one or more polypeptide chains less than about 200 amino acids long, and comprising a sequence sufficiently duplicative of the sequence of COP5, COP7, COP16, or OP1 such that said protein is capable of inducing cartilage formation in association with a matrix when implanted in a mammal.

23. The protein of claim 21 or 22 further characterized by being unglycosylated.

24. The protein of claim 21 or 22 comprising a pair of separate polypeptide chains.

25. The protein of claim 21 or 22 comprising the amino acid sequences:

	10	20	30	40	50
CXXXXLXVFXDXG	WXXX	XPXGXX	AXYCXGXCXX	PXXXXXXXX	NHAXX
	60	70	80	90	100
QXXVXXXNXXXXPXX	CCXPXXXXXX	XLXXXXXX	VXLXXYXX	MXVXXCXCX	

wherein each X independently represents an amino acid.

26. The protein of claim 21 or 22 comprising the amino acid sequences:

```

      10          20          30          40          50
    LXVFXDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXXNHAXX
      60          70          80          90         100
    QXXVXXXNXXXXPXXCCXPXXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
  
```

wherein each X independently represents an amino acid.

27. The protein of claim 21 or 22 comprising the amino acid sequences:

```

      10          20          30          40          50
    CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECFPPLADHLNSTNHAIV
    RKRS K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
    KE F E K I  DN   L   N S  Q  ITK F P  TL
      Q   A   S   K
      60          70          80          90         100
    QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
    SI HAI SEQV EP  A EQMNSLAI FFNDQDK I RK EE T DA H H
    RF  T  S   K DPV V  Y N S   H RN  RS
      N   S                   K   P   E
  
```

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position.

28. The protein of claim 21 or 22 comprising the amino acid sequences:

```

      10      20      30      40      50
LYVDFRDVGWNDWIVAPPGYHAFYCHGECPPFLADHLNSTNHAIV
  K S S L  Q E V I S E F D Y E A A Y M P E S M K A S  V I
  F E K I  D N      L      N S  Q  I T K F P      T L
      A      S      K
      60      70      80      90      100
QTLVNSVNP GKIPKACCVPT ELSAISMLYLDENENVVLK NYQDMVVEGCGCR
  S I H A I S E Q V E P  A E Q M N S L A I F F N D Q D K I R K E E T D A H H
  R F      T      S      K D P V V  Y N S      H R N      R S
  N      S                                  K      P      E

```

wherein, in each position where more than one amino acid is shown, any one of the amino acids shown may be in that position..

29. The protein of claim 21 or 22 comprising the amino acid sequences:

```

      1      10      20      30      40
Vg1  C K K R H L Y V E F K - D V G W Q N W V I A P Q G Y M A N Y C Y G E C P Y P L T E
      50      60      70
  I L N G S N - - H - A I L Q T L V H S I E P E D - I P L P C C V P T K M S P
      80      90      100
  I S M L F Y D N N D N V V L R H Y E N M A V D E C G C R

```

30. The protein of claim 21 or 22 comprising the amino acid sequences:

```

      1      10      20      30      40
DPP  C R R H S L Y V D F S - D V G W D D W I V A P L G Y D A Y Y C H G K C P F P L A D
      50      60      70
  H F N S T N - - H - A V V Q T L V N N N N P G K - V P K A C C V P T Q L D S
      80      90      100
  V A M L Y L N D Q S T V V L K N Y Q E M T V V G C G C R

```


31. The protein of claim 21 or 22 comprising the amino acid sequence:

```

      1      10      20      30      40
OP1      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPFLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90      100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
    
```

32. The protein of claim 21 or 22 comprising the amino acid sequences:

```

                                          -5
                                          HQRQA
      1      10      20      30      40
OP1      CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPFLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90      100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
    
```

33. The protein of claim 21 or 22 comprising the amino acid sequences:

```

      1      10      20      30      40
CBMP-2a  CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
              50      60      70
      HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTELSA
              80      90      100
      ISMLYLDENEKVVVLKNYQDMVVEGCGCR
    
```

34. The protein of claim 21 or 22 comprising the amino acid sequences:

```

CBMP-2b      1      10      20      30      40
              CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
                    50      60      70
              HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTELSA
                    80      90     100
              ISMLYLDEYDKVVLKKNYQEMVVEGCGCR
  
```

35. The protein of claim 21 or 22 comprising the amino acid sequences:

```

CBMP-3      1      10      20      30      40
              CARRYLKVDFA-DIGWSEWIIISPKSFDAYYCSGACQFPMPK
                    50      60      70
              SLKPSN--H-ATIQSIVRAVGVVPGIPEPCCVPEKMSS
                    80      90     100
              LSILFFDENKNVVLKVYPNMTVESACR
  
```

36. The protein of claim 21 or 22 comprising the amino acid sequences:

```

COP1      1      10      20      30      40
              LYVDFQRDVGWDDWIIAPVDFDAYYCSGACQFPSAD
                    50      60      70
              HFNSTN--H-AVVQTLVNNMNPVK-VPKPCCVPTELSA
                    80      90     100
              ISMLYLDENSTVVLKKNYQEMTVVGCGR
  
```

37. The protein of claim 21 or 22 comprising the amino acid sequences:

```

COP3      1      10      20      30      40
              LYVDFQRDVGWDDWIVAPPGYQAFYCSGACQFPSAD
                    50      60      70
              HFNSTN--H-AVVQTLVNNMNPVK-VPKPCCVPTELSA
                    80      90     100
              ISMLYLDENEKVVVLKKNYQEMVVEGCGCR
  
```

38. The protein of claim 21 or 22 comprising the amino acid sequences:

```

COP4      1      10      20      30      40
           LYVDFS-DVGWDDWIVAPPGYQAFYCSGACQFPSAD
                    50      60      70
           HFNSTN--H-AVVQTLVNNMNPBK-VPKCCVPTLSA
                    80      90     100
           ISMLYLDENEKVVVLKKNYQEMVVEGCGCR
    
```

39. The protein of claim 21 or 22 comprising the amino acid sequences:

```

COP5      1      10      20      30      40
           LYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
                    50      60      70
           HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
                    80      90     100
           ISMLYLDENEKVVVLKKNYQEMVVEGCGCR
    
```

40. The protein of claim 21 or 22 comprising the amino acid sequences:

```

COP7      1      10      20      30      40
           LYVDFS-DVGWDDWIVAPPGYHAFYCHGECPPFLAD
                    50      60      70
           HLNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
                    80      90     100
           ISMLYLDENEKVVVLKKNYQEMVVEGCGCR
    
```

41. The protein of claim 21 or 22 comprising the amino acid sequences:

```

COP16      1      10      20      30      40
           CRRHSLYVDFS-DVGWDDWIVAPPGYQAFYCHGECPPFLAD
                    50      60      70
           HFNSTN--H-AVVQTLVNSVNSKI--PKACCVPTLSA
                    80      90     100
           ISMLYLDENEKVVVLKKNYQEMVVEGCGCR
           -10
           PKHSSRARKKNKN
    
```

42. The protein of claim 21 or 22, comprising the product of expression of a DNA in a procaryotic cell.

43. A cell line engineered to express the protein of claim 21 or 22.

44. The protein of claim 21 having a half maximum bone forming activity of about 20 - 25 ng per 25 mg of implant.

45. Antibodies reactive with an epitope of the protein of claim 21 or 22.

46. The device of claim 1 or 2 wherein said matrix comprises demineralized, ~~deglycosylated,~~ protein extracted, particulate, xenogenic bone.

47. The device of claim 1 or 2 wherein said matrix comprises demineralized, protein-extracted, particulate, xenogenic bone treated with HF.

FIG. 1-1

COP1	COP5	COP3	COP4	COP7	VG1	DPP	OPI	CBMP2	CBMP3	beta-Inhibin	TGF-beta	MIS	alpha-Inhib	consensus choices
<P	P	P	P	P	C	C	C	C	C	C	C	C	C	C
N	N	N	N	N	K	R	R	R	A	C	C	A	H	k,r
G	N	G	N	G	K	R	H	R	R	C	V	L	R	k,r
L	G	L	G	L	R	H	P	R	R	C	R	R	V	h,k,r,q
Y	G	L	G	L	S	L	L	Y	Y	C	Q	R	A	p,s,e,q
V	L	Y	V	L	S	L	V	V	L	C	L	S	V	l
D	Y	V	V	Y	V	V	D	D	F	C	I	V	N	y,f
D	V	D	D	V	D	V	F	F	I	C	D	D	I	v,i
F	F	F	F	F	F	F	S	S	D	C	F	R	S	d,e,s
Q	F	F	F	F	K	S	F	F	A	C	R	A	F	f
R	Q	R	R	S	K	S	K	R	A	C	K	R	Q	k,r,s
D	R	D	D	S	D	D	D	D	D	C	D	A	E	d
V	V	V	V	S	V	G	W	W	S	C	L	E	L	v,l,i
G	G	G	G	S	W	Q	N	W	E	C	W	E	R	g
W	W	W	W	S	Q	N	W	V	S	C	W	E	R	w
D	D	D	D	S	N	W	V	I	E	C	-	A	W	q,n,d,e,s
D	D	D	D	S	W	V	I	A	S	C	W	E	R	d,e,n
W	I	I	I	S	V	I	A	P	S	C	I	V	W	w
I	I	A	A	S	A	A	P	P	S	C	V	L	W	i,v
A	P	P	P	S	P	A	P	P	S	C	I	P	W	i,v
V	D	F	G	Y	Q	G	Y	H	A	C	E	P	Y	a,s
D	F	D	G	Y	M	L	G	Y	D	C	P	P	P	p
A	A	Q	Q	A	A	A	A	A	A	C	K	E	P	e,q,p*
A	A	Q	Q	A	A	A	A	A	A	C	G	T	S	g,s
A	A	Q	Q	A	A	A	A	A	A	C	Y	Y	I	y,f
A	A	Q	Q	A	A	A	A	A	A	C	H	N	I	h,d,n,q,y*
A	A	Q	Q	A	A	A	A	A	A	C	F	Y	F	a
A	A	Q	Q	A	A	A	A	A	A	C	A	A	F	

FIG. 1-4

```

n,k
v,i
v,i
l
k,r
n,d,k*
y
q,e,p,r
n,d,e
m
v,i,t,a
v
e,d,r,k,
g,a,s,e
c
g,h
c
r,h,s,a,
:::
:::
:::
:::
:::
:::
:::
:::
:::
:::
:::
:::
G G Y S F K Y E TVP N L L T Q H C A C I
I S A H H V P N M V A T E C G C R
: : V : : : : : : : : : : : :
P K V E Q L S N M I V R S C K C S
N I V K R D V P N M I V E E C G C A
N I I K K D I Q N M I V E E C G C S
N V V L K V Y P N M T V E S C H C R
: : : : : : : : : : : : : :
E
K V V L K N Y Q D M V V E G C G C R
N V I L K K Y R N M V V R A C G C H
T V V L K N Y Q E M T V V G C G C R
N V V L R H Y E N M A V D E C G C R
: : : : : : : : : : : : : :
K K V V L K N Y Q E M V V E G C G C R
K V V L K N Y Q E M V V E G C G C R
K V V L K N Y Q E M V V E G C G C R
K V V L K N Y Q E M V V E G C G C R
K V V L K N Y Q E M V V E G C G C R

```





FIG. 2A

6 / 10

FIG. 2B-1

COP-5 fusion protein

10 20 30 40 50
 ATGAAAGCAATTTTCGTA CTGAAAGGTTCACTGGACAGAGATCTGGACTC
 M K A I F V L K G S L D R D L D S
 BglIII

60 70 80 90 100
 TCGTCTGGATCTGGACGTTTCGTACCGACCACAAAGACCTGTCTGATCACC
 R L D L D V R T D H K D L S D H

110 120 130 140 150
 TGGTTCTGGTTCGACCTGGCTCGTAACGACCTGGCTCGTATCGTTACTCCC
 L V L V D L A R N D L A R I V T P
 SalI Sma

160 170 180 190 200
 GGGTCTCGTTACGTTGCGGATCTGGAATTCATGGCTGACAACAAATTCAA
 G S R Y V A D L E F M A D N K F N
 I EcoRI

210 220 230 240 250
 CAAGGAACAGCAGAACGCGTTCTACGAGATCTTGCACCTGCCGAACCTGA
 K E Q Q N A F Y E I L H L P N L
 MluI BglIII BspMI+

260 270 280 290 300
 ACGAAGAGCAGCGTAACGGCTTCATCCAAAGCTTGAAGGATGAGCCCTCT
 N E E Q R N G F I Q S L K D E P S
 HindIII

310 320 330 340 350
 CAGTCTGCGAATCTGCTAGCGGATGCCAAGAACTGAACGATGCCGACGGC
 Q S A N L L A D A K K L N D A Q A
 NheI FspI

360 370 380 390 400
 ACCGAAATCGGATCAGGGGCAATTCATGGCTGACAACAAATTCAACAAGG
 P K S D Q G Q F M A D N K F N K

410 420 430 440 450
 AACAGCAGAACGCGTTCTACGAGATCTTGCACCTGCCGAACCTGAACGAA
 E Q Q N A F Y E I L H L P N L N E
 MluI BglIII BspMI+

460 470 480 490 500
 GAGCAGCGTAACGGCTTCATCCAAAGCTTGAAGGATGAGCCCTCTCAGTC
 E Q R N G F I Q S L K D E P S Q S
 HindIII

FIG. 2B-2

510 520 530 540 550
 TCGGAATCTGCTAGCGGATGCCAAGAACTGAACGATGCCGAGGCACCGA
 A N L L A D A K K L N D A Q A P
 NheI FspI

560 570 580 590 600
 AGGATCCTAATGGGCTGTACGTCGACTTCAGCGACGTGGGCTGGGACGAC
 K D P N G L Y V D F S D V G W D D
 BamHI Sali

610 620 630 640 650
 TGGATTGTGGCCCCACCAGGCTACCAGGCCTTCTACTGCCATGGCGAATG
 W I V A P P G Y Q A F Y C H G E C
 StuI NcoI BsmI+

660 670 680 690 700
 CCCTTTCCCGCTAGCGGATCACTTCAACAGCACCAACCACGCCGTGGTGC
 P F P L A D H F N S T N H A V V
 NheI DraIII
 PflMI

710 720 730 740 750
 AGACCCTGGTGAACCTCTGTCAACTCCAAGATCCCTAAGGCTTGCTGCGTG
 Q T L V N S V N S K I P K A C C V
 MstII

760 770 780 790 800
 CCCACCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATGAGAA
 P T E L S A I S M L Y L D E N E K
 SphI

810 820 830 840 850
 GGTGGTGTGAAGAACTACCAGGAGATGGTAGTAGAGGGCTGCCGGCTGCC
 V V L K N Y Q E M V V E G C G C
 PflMI

860
 GCTAACTGCAG
 R *
 PstI

FIG. 3A




FIG. 3B



10 / 10

FIG. 4

10 20 30 40 50
GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACGA
D P N G L Y V D F Q R D V G W D D

60 70 80 90 100
CTGGATCATCGCCCCGTCGACTTCGACGCCTACTACTGCTCCGGAGCCT
W I I A P V D F D A Y Y C S G A

110 120 130 140 150
GCGAGTCCCCTCTGCGGATCACTTCAACAGCACCAACCACGCCGTGGTG
C Q F P S A D H F N S T N H A V V

160 170 180 190 200
CAGACCCTGGTGAACAACATGAACCCCGGCAAGGTACCCAAGCCCTGCTG
Q T L V N N M N P G K V P K P C C

210 220 230 240 250
CGTGCCACCCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATT
V P T E L S A I S M L Y L D E N

260 270 280 290 300
CCACCGTGGTGTGAAGAACTACCAGGAGATGACCGTGGTGGGCTGCGGC
S T V V L K N Y Q E M T V V G C G

310
TGCCGCTAACTGCAG
C R *

SUBSTITUTE SHEET



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent Classification 4: C12N 15/00, C12P 21/02, A61L 27/00 C07K 13/00, A61K 37/36, //A61K 35/32	A3	(11) International Publication Number: WO 89/09788 (43) International Publication Date: 19 October 1989 (19.10.89)
(21) International Application Number: PCT/US89/01469 (22) International Filing Date: 7 April 1989 (07.04.89) (30) Priority data: 179,406 8 April 1988 (08.04.88) US 232,630 15 August 1988 (15.08.88) US 315,342 23 February 1989 (23.02.89) US (60) Parent Applications or Grants (63) Related by Continuation US 179,406 (CIP) Filed on 8 April 1988 (08.04.88) US 232,630 (CIP) Filed on 15 August 1988 (15.08.88) US 315,342 (CIP) Filed on 23 February 1988 (23.02.88) (71) Applicant (for all designated States except US): CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): OPPERMAN, Hermann [US/US]; 25 Summer Hill Road, Medway, MA 02053 (US). KUBERASAMPATH, Thangavel [IN/US]; 6 Spring Street, Medway, MA 02053 (US). RUEGER, David, C. [US/US];	150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin [TR/US]; 44 Purdue Drive, Milford, MA 01757 (US). (74) Agent: PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US). (81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 8 February 1990 (08.02.90)	
(54) Title: BIOSYNTHETIC OSTEOGENIC PROTEINS AND OSTEOGENIC DEVICES CONTAINING THEM		
(57) Abstract <p>Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth and cartilage in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.</p>		


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US 89/01469**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁴ : C 12 N 15/00, C 12 P 21/02, A 61 L 27/00, C 07 K 13/00, A 61 K 37/36, // A 61 K 35/32		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁴	C 07 K, C 12 N, C 12 P, A 61 K, A 61 L	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO, A, 88/00205 (GENETICS INSTITUTE) 14 January 1988 see pages 1-12, 15, 16, 17, 22-24, 49; pages 61-73, claims 1-23 cited in the application	1-6, 11, 12, 20-28, 42, 43, 46, 47
Y	--	7-10, 13- 19, 29-32, 36-41, 44, 45
Y	Cell, volume 51, 4 December 1987, Cell Press, D.L. Weeks et al.: "A maternal mRNA localized to the vegetal hemisphere in Xenopus eggs codes for a growth factor related to TGF- β ", pages 861- 867 see the whole article, especially figure 3	7-10, 13- 19, 29-32, 36-41
Y	Nature, volume 325, 1 January 1987, R.W. Padgett et al.: "A transcript from a Drosophila pattern gene ./.	7-10, 13- 19, 29-32, 36-41
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
8th November 1989	15. 01. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 T.K. WILLIS	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	predicts a protein homologous to the transforming growth factor- β family", pages 81-84 see figure 2 on page 82; figure 3, on page 83; figure 4 on page 84 --	
Y	The Journal of Cell Biology, volume 97, December 1983, The Rockefeller University Press, S.M. Seyedin et al.: "In vitro induction of cartilage-specific macromolecules by a bone extract", pages 1950-1953 see the whole article, especially page 1952, right-hand column --	21-41
Y	US, A, 4563350 (NATHAN et al.) 7 January 1986 see column 3, lines 30-40; column 5, lines 5-10; column 7, lines 45-60; column 10, lines 45-50 --	1,2,21,22, 42,43,46, 47
Y	EP, A, 0128041 (BAYLINK) 12 December 1984 see pages 27-28, claims --	1,2,45
A	EP, A, 0169016 (COLLAGEN CORP.) 22 January 1986 see pages 19-20, claims 1-7 --	1,2,21,22, 42,43,46, 47
A	EP, A, 0212474 (UNIVERSITY OF CALIFORNIA) 4 March 1987 --	
A	Science, volume 217, 27 August 1982, AAAS, T.H. Maugh II: "Human skeletal growth factor isolated", page 819 --	
A	S.P. Colowick et al.: "Methods in Enzymology", volume 146, "Peptide Growth Factors", part A, edited by D. Barnes et al., published by Academic Press, Inc., M. R. Urist et al.: "Preparation and bioassay of bone morphogenetic protein and polypeptide fragments", pages 294-312 --	
P,X	Science, volume 242, 16 December 1988, J.M. Wozney et al.: "Novel regulators of bone formation: molecular clones and activities", pages 1528-1534 ./..	1-6,11,12, 20-28,42, 43,46,47

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	see the whole article cited in the application --	
L *	World Patent Information, volume 11, no. 1, 1989, Pergamon Orbit InfoLine Inc., (GB), K.E.H. Göhring et al.: "A giant step for mankind?", pages 5-10 see the whole article *(in connection with the declaration of incomplete search, see PCT/ISA/210 (Supplemental sheet 2)) --	1-47
L *	Proceedings of the Montreux 1989 International Chemical Information Conference, Montreux, CH, 26-28 September 1989, edited by Harry R. Collier, published by Infonortics Ltd, (Calne) C. Suhr: "Hypertrophic generic structures in patent claims: an extravagance and a remedy for it", pages 131-139 see the whole article *(in connection with the declaration of incomplete search, see PCT/ISA/210 (Supplemental sheet 2)) -----	1-47

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

pls. see attached sheet

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. claims 7 and 29 totally; 1 - 6, 20 - 28 and 42 - 47 partially
2. claims 8 and 30 totally; 1 - 6, 20 - 28 and 42 - 47 partially
3. claims 9, 10 and 31, 32 totally; 1 - 6, 20 - 28 and 42 - 47 partially
4. claims 11, 12 and 33, 34 totally; 1 - 6, 20 - 28 and 42 - 47 partially
5. claims 13 and 35 totally; 1 - 6, 20 - 28 and 42 - 47 partially ./.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 (supplemental sheet (2))

The present application is admittedly NOT the first to describe the phenomenon of bone inducing proteins, or devices containing them. It is therefore necessarily drafted to the individual compounds on well-known devices.

In claim 3, for example, a protein (on a device) is claimed, which comprises 103 amino acids, whereof 68 are completely unspecified. Even if it is assumed that "amino acid" means "natural alpha amino acid", and that "comprises" means "consisting of exactly", the formula would still cover 20⁶⁸ different compounds. The scope of the claims 1 and 2 is even vaster. (Despite this broad scope, the biological activity has only been demonstrated for the compounds COP5, COP7, COP16, and OP1, corresponding to subjects 3 and 7 of the non unity declaration!).

Formulas of the type of claim 3 cannot validly be regarded as a concise description of the matter for which protection is sought, all the more as the few defined amino acids are totally dispersed in the hypothetical peptide chain. The search has therefore been restricted to the embodiments of claims 1-47, in as far as the protein sequences correspond to the sequences disclosed in the claims 7-16 (or 29-41).

~~This searchable subject matter has been regrouped according to the non-unity specification, in order to establish conceptually individual subjects, each of which now constitutes a potential selection invention. (Please see also the citations "A giant step..." and "Hypertrophic Patent Claims...").~~

xx 6. claims 14 - 16 and 36 - 38 totally; 1 - 6, 20 - 28 and 42 - 47 partially
7. claims 17 - 19 and 39 - 41 totally; 1 - 6, 20 - 28 and 42 - 47 partially

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8901469
SA 28080

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 19/12/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8800205	14-01-88	AU-A- 7783587	29-01-88
		EP-A- 0313578	03-05-89
US-A- 4563350	07-01-86	AU-B- 585268	15-06-89
		AU-A- 4900585	01-05-86
		EP-A- 0182483	28-05-86
		JP-A- 62016421	24-01-87
EP-A- 0128041	12-12-84	CA-A- 1229789	01-12-87
		JP-A- 60069020	19-04-85
EP-A- 0169016	22-01-86	AU-A- 4501585	23-01-86
		CA-A- 1261549	26-09-89
		JP-A- 61036223	20-02-86
		US-A- 4774322	27-09-88
		US-A- 4774228	27-09-88
		US-A- 4810691	07-03-89
		US-A- 4843063	27-06-89
EP-A- 0212474	04-03-87	US-A- 4795804	03-01-89
		JP-A- 62111933	22-05-87

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent Classification 4: C12N 15/00, C12P 21/02, A61L 27/00 C07K 13/00, A61K 37/36, //A61K 35/32		A3	(11) International Publication Number: WO 89/09788
			(43) International Publication Date: 19 October 1989 (19.10.89)
(21) International Application Number: PCT/US89/01469		150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin [TR/US]; 44 Purdue Drive, Milford, MA 01757 (US).	
(22) International Filing Date: 7 April 1989 (07.04.89)			
(30) Priority data:		(74) Agent: PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).	
179,406 8 April 1988 (08.04.88) US		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.	
232,630 15 August 1988 (15.08.88) US			
315,342 23 February 1989 (23.02.89) US			
(60) Parent Applications or Grants			
(63) Related by Continuation			
US 179,406 (CIP)		Published <i>With international search report</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
Filed on 8 April 1988 (08.04.88)			
US 232,630 (CIP)			
Filed on 15 August 1988 (15.08.88)			
US 315,342 (CIP)			
Filed on 23 February 1988 (23.02.88)		(88) Date of publication of the international search report: 8 February 1990 (08.02.90)	
(71) Applicant (for all designated States except US): CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): OPPERMANN, Hermann [US/US]; 25 Summer Hill Road, Medway, MA 02053 (US). KUBERASAMPATH, Thangavel [IN/US]; 6 Spring Street, Medway, MA 02053 (US). RUEGER, David, C. [US/US];			
(54) Title: BIOSYNTHETIC OSTEOGENIC PROTEINS AND OSTEOGENIC DEVICES CONTAINING THEM			
(57) Abstract			
Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth and cartilage in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.			


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Fasso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US 89/01469**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁴ : C 12 N 15/00, C 12 P 21/02, A 61 L 27/00, C 07 K 13/00, A 61 K 37/36, // A 61 K 35/32		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁴	C 07 K, C 12 N, C 12 P, A 61 K, A 61 L	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO, A, 88/00205 (GENETICS INSTITUTE) 14 January 1988 see pages 1-12, 15, 16, 17, 22-24, 49; pages 61-73, claims 1-23 cited in the application	1-6, 11, 12, 20-28, 42, 43, 46, 47
Y		7-10, 13- 19, 29-32, 36-41, 44, 45
Y	Cell, volume 51, 4 December 1987, Cell Press, D.L. Weeks et al.: "A maternal mRNA localized to the vegetal hemisphere in Xenopus eggs codes for a growth factor related to TGF- β ", pages 861- 867 see the whole article, especially figure 3	7-10, 13- 19, 29-32, 36-41
Y	Nature, volume 325, 1 January 1987, R.W. Padgett et al.: "A transcript from a Drosophila pattern gene ./. "	7-10, 13- 19, 29-32, 36-41
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
8th November 1989	15. 01. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 T.K. WILLIS	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	predicts a protein homologous to the transforming growth factor- β family", pages 81-84 see figure 2 on page 82; figure 3, on page 83; figure 4 on page 84 --	
Y	The Journal of Cell Biology, volume 97, December 1983, The Rockefeller University Press, S.M. Seyedin et al.: "In vitro induction of cartilage-specific macromolecules by a bone extract", pages 1950-1953 see the whole article, especially page 1952, right-hand column --	21-41
Y	US, A, 4563350 (NATHAN et al.) 7 January 1986 see column 3, lines 30-40; column 5, lines 5-10; column 7, lines 45-60; column 10, lines 45-50 --	1,2,21,22, 42,43,46, 47
Y	EP, A, 0128041 (BAYLINK) 12 December 1984 see pages 27-28, claims --	1,2,45
A	EP, A, 0169016 (COLLAGEN CORP.) 22 January 1986 see pages 19-20, claims 1-7 --	1,2,21,22, 42,43,46, 47
A	EP, A, 0212474 (UNIVERSITY OF CALIFORNIA) 4 March 1987 --	
A	Science, volume 217, 27 August 1982, AAAS, T.H. Maugh II: "Human skeletal growth factor isolated", page 819 --	
A	S.P. Colowick et al.: "Methods in Enzymology", volume 146, "Peptide Growth Factors", part A, edited by D. Barnes et al., published by Academic Press, Inc., M. R. Urist et al.: "Preparation and bioassay of bone morphogenetic protein and polypeptide fragments", pages 294-312 --	
P,X	Science, volume 242, 16 December 1988, J.M. Wozney et al.: "Novel regulators of bone formation: molecular clones and activities", pages 1528-1534 ./..	1-6,11,12, 20-28,42, 43,46,47

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
------------	--	----------------------

- | | | |
|-----|--|------|
| | <p>see the whole article
cited in the application</p> <p>--</p> | |
| L * | <p>World Patent Information, volume 11, no. 1,
1989, Pergamon Orbit InfoLine Inc.,
(GB),
K.E.H. Göhring et al.: "A giant step
for mankind?", pages 5-10
see the whole article
*(in connection with the declaration of incomplete
search, see PCT/ISA/210 (Supplemental sheet 2))</p> <p>--</p> | 1-47 |
| L * | <p>Proceedings of the Montreux 1989
International Chemical Information
Conference, Montreux, CH, 26-28
September 1989, edited by Harry R.
Collier, published by Infonortics Ltd,
(Calne)
C. Suhr: "Hypertrophic generic
structures in patent claims: an
extravagance and a remedy for it",
pages 131-139
see the whole article
*(in connection with the declaration of incomplete
search, see PCT/ISA/210 (Supplemental sheet 2))</p> <p>-----</p> | 1-47 |

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

pls. see attached sheet

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(e).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. claims 7 and 29 totally; 1 - 6, 20 - 28 and 42 - 47 partially
2. claims 8 and 30 totally; 1 - 6, 20 - 28 and 42 - 47 partially
3. claims 9, 10 and 31, 32 totally; 1 - 6, 20 - 28 and 42 - 47 partially
4. claims 11, 12 and 33, 34 totally; 1 - 6, 20 - 28 and 42 - 47 partially
5. claims 13 and 35 totally; 1 - 6, 20 - 28 and 42 - 47 partially ./.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.

- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 (supplemental sheet (2))

The present application is admittedly NOT the first to describe the phenomenon of bone inducing proteins, or devices containing them. It is therefore necessarily drafted to the individual compounds on well-known devices.

In claim 3, for example, a protein (on a device) is claimed, which comprises 103 amino acids, whereof 68 are completely unspecified. Even if it is assumed that "amino acid" means "natural alpha amino acid", and that "comprises" means "consisting of exactly", the formula would still cover 2068 different compounds. The scope of the claims 1 and 2 is even vaster. (Despite this broad scope, the biological activity has only been demonstrated for the compounds COP5, COP7, COP16, and OP1, corresponding to subjects 3 and 7 of the non unity declaration!).

Formulas of the type of claim 3 cannot validly be regarded as a concise description of the matter for which protection is sought, all the more as the few defined amino acids are totally dispersed in the hypothetical peptide chain. The search has therefore been restricted to the embodiments of claims 1-47, in as far as the protein sequences correspond to the sequences disclosed in the claims 7-16 (or 29-41).

This searchable subject matter has been regrouped according to the non-unity specification, in order to establish conceptually individual subjects, each of which now constitutes a potential selection invention. (Please see also the citations "A giant step..." and "Hypertrophic Patent Claims...").

xx 6. claims 14 - 16 and 36 - 38 totally; 1 - 6, 20 - 28 and 42 - 47 partially
7. claims 17 - 19 and 39 - 41 totally; 1 - 6, 20 - 28 and 42 - 47 partially

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 8901469
SA 28080

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 19/12/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8800205	14-01-88	AU-A- 7783587	29-01-88
		EP-A- 0313578	03-05-89
US-A- 4563350	07-01-86	AU-B- 585268	15-06-89
		AU-A- 4900585	01-05-86
		EP-A- 0182483	28-05-86
		JP-A- 62016421	24-01-87
EP-A- 0128041	12-12-84	CA-A- 1229789	01-12-87
		JP-A- 60069020	19-04-85
EP-A- 0169016	22-01-86	AU-A- 4501585	23-01-86
		CA-A- 1261549	26-09-89
		JP-A- 61036223	20-02-86
		US-A- 4774322	27-09-88
		US-A- 4774228	27-09-88
		US-A- 4810691	07-03-89
EP-A- 0212474	04-03-87	US-A- 4795804	03-01-89
		JP-A- 62111933	22-05-87